Skip to main content

Table 3 Peptide cocktail-specific CTL precursor frequency during DC vaccination

From: Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells

  

Spot No./CD8+T cell (%)a

Patient No.

DC injection (times)

before

day29

day78

day134

day190

1

1 × 107(10)

1.19/0.45

6.96/0.06

8.82/0.63

8.81/0.08

5.4/0.08

2

1 × 107(10)

0.07/0.05

0.07/0.2

0.02/0

0.02/0

0.29/0.03

3

1 × 107(3)

N.D.b

N.A.c

N.A.

N.A.

N.A.

4

2 × 107(6)

0.39/0.53

1.29/0.03

1.12/0

N.A.

N.A.

5

2 × 107(6)

1.74/0.05

0.51/0.2

1.25/0.04

N.A

N.A.

6

2 × 107(10)

0.21/0.27

0.31/0.28

1.18/0.24

7.80/0.19

9.82/0.30

7

5 × 107(8)

0.62/0.20

6.52/0.1

7.33/0.11

N.A.

N.A.

8

5 × 107(3)

N.D.

N.A.

N.A.

N.A.

N.A.

9

5 × 107(3)

3.09/1.24

N.D.

N.A.

N.A.

N.A.

  1. The percentages represent IFN-γ-positive spot No. divided by total CD8+ cell No. from 1 × 104 PBMCs. aEach value represents the percentage with peptide cocktail/without peptide cocktail. bN.D. ; not done, cN.A. ; sample not available.